Profile data is unavailable for this security.
About the company
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
- Revenue in USD (TTM)0.00
- Net income in USD-20.94m
- Incorporated2021
- Employees5.00
- LocationAllarity Therapeutics Inc24 School St., 2Nd FloorBOSTON 02108United StatesUSA
- Phone+1 (401) 426-4664
- Fax+1 (302) 655-5049
- Websitehttps://allarity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 10.04m | 5.00 | -- | 2.26 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
Psyence Biomedical Ltd | 0.00 | 1.52m | 10.04m | -- | -- | -- | 6.63 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
Eterna Therapeutics Inc | 115.00k | -22.92m | 10.28m | 8.00 | -- | -- | -- | 89.39 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Universe Pharmaceuticals Inc | 32.31m | -6.16m | 10.66m | 225.00 | -- | 0.268 | -- | 0.3299 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
Monopar Therapeutics Inc | 0.00 | -7.61m | 10.68m | 10.00 | -- | 1.43 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
Scorpius Holdings Inc | 9.74m | -32.20m | 10.73m | 82.00 | -- | 0.1399 | -- | 1.10 | -1.22 | -1.40 | 0.3663 | 0.7937 | 0.1372 | -- | 26.56 | 118,815.70 | -47.81 | -39.37 | -58.20 | -43.18 | 68.56 | -- | -348.43 | -1,068.21 | 0.2641 | -198.18 | 0.3179 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
Vaccinex Inc | 124.00k | -19.19m | 10.74m | 37.00 | -- | 7.57 | -- | 86.63 | -46.02 | -46.02 | 0.1685 | 1.68 | 0.0202 | -- | 0.0894 | 3,351.35 | -312.93 | -262.29 | -731.45 | -- | -- | -- | -15,472.58 | -4,257.17 | -- | -55.90 | 0.03 | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
Medical Marijuana Inc | -100.00bn | -100.00bn | 10.80m | -- | -- | 0.0999 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
Allarity Therapeutics Inc | 0.00 | -20.94m | 10.85m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 10.91m | 20.00 | -- | -- | -- | 839.55 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
Bon Natural Life Ltd | 29.52m | 4.60m | 10.92m | 96.00 | 0.5511 | 0.091 | 1.98 | 0.3699 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
Moleculin Biotech Inc | 0.00 | -26.82m | 11.03m | 18.00 | -- | 0.5108 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
CV Sciences Inc | 15.86m | -3.23m | 11.10m | 42.00 | -- | 4.70 | -- | 0.6999 | -0.0207 | -0.0207 | 0.1012 | 0.0145 | 1.59 | 1.42 | 27.25 | 377,571.40 | -32.43 | -43.42 | -83.71 | -77.75 | 45.13 | 51.81 | -20.38 | -45.68 | 0.2677 | -13.32 | 0.0472 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
Holder | Shares | % Held |
---|---|---|
UBS Securities LLCas of 31 Mar 2024 | 1.65k | 0.07% |
Tower Research Capital LLCas of 31 Mar 2024 | 286.00 | 0.01% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 2.00 | 0.00% |
Two Sigma Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Virtu Americas LLCas of 31 Mar 2024 | 0.00 | 0.00% |